Dr. Martin K. Kankam

Internal Medicine
4101 S 4th St, 
Leavenworth, KS 
4101 S 4th St, 
Leavenworth, KS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Martin Kankam is a primary care provider, practicing in Internal Medicine in Leavenworth, Kansas. His top areas of expertise are Gout, Hepatitis A, Headache, and Obesity.

His clinical research consists of co-authoring 25 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in KS
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

4101 S 4th St, Leavenworth, KS 66048

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Two-part, Randomized, Double-blind, Single-dose, Crossover Study to Compare Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Adult Volunteers
A Two-part, Randomized, Double-blind, Single-dose, Crossover Study to Compare Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Adult Volunteers
Enrollment Status: Completed
Publish Date: April 10, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Double-Blind, Placebo-Controlled Randomized Study to Assess Repeated Doses of INDV-2000 (C4X_3256) up to 28 Days in Healthy Volunteers, and an Open-Label Study of INDV-2000 up to 11 Days in Treatment Seeking Individuals With Opioid Use Disorder
A Phase I Double-Blind, Placebo-Controlled Randomized Study to Assess Repeated Doses of INDV-2000 (C4X_3256) up to 28 Days in Healthy Volunteers, and an Open-Label Study of INDV-2000 up to 11 Days in Treatment Seeking Individuals With Opioid Use Disorder
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SBP-9330 (With a Nested Food-Effect Arm) After Oral Administration in Healthy Subjects
A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SBP-9330 (With a Nested Food-Effect Arm) After Oral Administration in Healthy Subjects
Enrollment Status: Completed
Publish Date: April 16, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2B, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversing Ticagrelor in Subjects Aged 50 to 80 Years Old
A Phase 2B, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversing Ticagrelor in Subjects Aged 50 to 80 Years Old
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Drug
Study Phase: Phase 2
Randomized, Double-blind, Placebo-controlled, Pharmacokinetic, Pharmacodynamic Study of Trans Sodium Crocetinate Utilizing Transcutaneous Oximetry Measurement in Healthy Volunteers
Randomized, Double-blind, Placebo-controlled, Pharmacokinetic, Pharmacodynamic Study of Trans Sodium Crocetinate Utilizing Transcutaneous Oximetry Measurement in Healthy Volunteers
Enrollment Status: Completed
Publish Date: July 11, 2023
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Randomized, Single-dose, Two-period, Two-treatment (Fed vs Fasted), Two-sequence, Crossover Study in Healthy Adult Subjects to Assess the Effect of Food on the Absorption and Bioavailability of CTx-1301 (Dexmethylphenidate)
An Open-label, Randomized, Single-dose, Two-period, Two-treatment (Fed vs Fasted), Two-sequence, Crossover Study in Healthy Adult Subjects to Assess the Effect of Food on the Absorption and Bioavailability of CTx-1301 (Dexmethylphenidate)
Enrollment Status: Completed
Publish Date: October 20, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 in Healthy Subjects
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 in Healthy Subjects
Enrollment Status: Completed
Publish Date: July 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 6 Less Clinical Trials

25 Total Publications

A Once-Daily GLP-1/GIP/Glucagon Receptor Tri-agonist (NN1706) Lowers Body Weight in Rodents, Monkeys and Humans.
A Once-Daily GLP-1/GIP/Glucagon Receptor Tri-agonist (NN1706) Lowers Body Weight in Rodents, Monkeys and Humans.
Journal: Molecular metabolism
Published: February 10, 2025
Similar Doctors
Expertise in
74
conditions
Dr. Vikas Agarwal
Internal Medicine
Expertise in
74
conditions
Dr. Vikas Agarwal
Internal Medicine

Heartland Regional Medical Center

5325 Faraon St, Suite R, 
Saint Joseph, MO 
 (34.9 miles away)
816-271-6870
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Vikas Agarwal is a primary care provider, practicing in Internal Medicine in Saint Joseph, Missouri. Dr. Agarwal is highly rated in 74 conditions, according to our data. His top areas of expertise are Myositis, COVID-19, Takayasu Arteritis, Kidney Transplant, and Vertebroplasty. Dr. Agarwal is currently accepting new patients.

Patrick M. Moriarty
Expertise in
14
conditions
Dr. Patrick M. Moriarty
Internal Medicine
Expertise in
14
conditions
Dr. Patrick M. Moriarty
Internal Medicine

Kansas University Physicians Inc

3901 Rainbow Blvd, 
Kansas City, KS 
 (21.7 miles away)
913-588-7775
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Moriarty is a primary care provider, practicing in Internal Medicine in Kansas City, Kansas. Dr. Moriarty is highly rated in 14 conditions, according to our data. His top areas of expertise are High Cholesterol, Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia (HoFH), and Defective Apolipoprotein B-100. Dr. Moriarty is currently accepting new patients.

Expertise in
70
conditions
Dr. Peter Cristiano
Internal Medicine
Expertise in
70
conditions
Dr. Peter Cristiano
Internal Medicine

Leavenworth Family Health Center

720 1st Ter, 
Lansing, KS 
 (2.8 miles away)
913-682-5588
Languages Spoken:
English
See accepted insurances

Peter Cristiano is a primary care provider, practicing in Internal Medicine in Lansing, Kansas. Dr. Cristiano is highly rated in 70 conditions, according to our data. His top areas of expertise are Tracheitis, Hypothyroidism, Renovascular Hypertension, and Familial Hypercholesterolemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kankam's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile